Cognitive Fitness Through Nootropics: The Brain Training Trend
In the summer of 2026, the fitness focus shifts toward cognitive abilities. The market for nootropic supplements to improve memory, focus, and mental endurance is growing rapidly, offering solutions to combat fatigue.
Analytical Digest: Cognitive Fitness Through Nootropics — Why Athletes and Office Workers Now Compete in the Same Race
The sports nutrition industry is experiencing its most significant shift in a decade. What the media calls the "cognitive fitness trend" is actually a fundamental restructuring of how we understand athletic performance. It's no longer enough to be just strong or resilient — today, the winner is the one who makes the best decisions under pressure.
The nootropics market is experiencing explosive growth. The global nootropics market grew from $5.96 billion in 2025 to $6.96 billion in 2026, showing a CAGR of 16.9%, and is projected to reach $13.23 billion by 2030. Meanwhile, the market for functional foods and beverages for brain health is growing even faster: from $23.02 billion in 2025 to $25.58 billion in 2026 (CAGR 11.1%). This is not just a fad — it's a structural shift in consumer demand.
[The Core]: What's Really Happening
The true essence of the trend lies in redefining "athletic performance." According to a presentation by doctoral candidate Megan Leonard at the ISSN conference, cognitive function includes not only memory but also attention, psychomotor abilities, information processing speed, logic, problem-solving, and verbal skills. All these domains are critically important for athletes, especially in team sports — football, basketball, tennis, martial arts.
But the insight most observers miss is this: nootropics are not "smart pills" that make you a genius. They are tools for maintaining peak performance provided the foundation is already laid. As Leonard emphasizes, sleep, exercise, nutrition, and mental health remain the four fundamental pillars of cognitive health. Nootropics cannot compensate for chronic sleep deprivation or nutrient deficiencies.
At the same time, the evidence base for many nootropic ingredients already exists. Caffeine remains the gold standard: it improves reaction time, accuracy, and information processing speed at low to moderate doses taken about an hour before activity. However, caffeine's effectiveness depends on genetics — fast metabolizers get optimal effects, while slow metabolizers experience limited benefits and increased side effects.
Timeline and Context
The journey of nootropics from a niche "biohacker" segment to the mainstream took about five years. Key points that the media ignore:
- 2021-2022 (Origination): The pandemic and remote work era created mass demand for focus and productivity products. The market begins to notice ingredients like L-theanine and Rhodiola rosea.
- 2023 (Transition): Esports becomes a trend driver. Gamers need products for sustained focus without caffeine crashes. The first "smart" pre-workouts with nootropic stacks appear.
- 2024 (Massification): Mintel notes that the share of sports nutrition launches with brain health claims rose from 11% in 2016 to 17% in 2026. Ashwagandha becomes a star: its sales grow 77% year-over-year, and green caffeine shows 313% growth.
- 2025 (Validation): Major studies on athlete populations are published. Ashwagandha KSM-66 gains endorsement from stars like Robert Lewandowski, who becomes a global brand ambassador.
- Early 2026 (Current Moment): The market reaches a tipping point. Grand View Research forecasts: the global nootropics market will reach $11.5 billion by 2033, up from $5.5 billion in 2025. North America remains the largest region, but the Asia-Pacific region shows the fastest growth.
Who Wins and Who Loses
Winners #1: Manufacturers of beverages and electrolytes with nootropic properties. According to Innova, nutrition drinks dominate with 76% of launches containing nootropic claims. New Zealand brand Heights launched Hydrate — an electrolyte with citicoline that took five years to develop. Citicoline (Cognizin from Kyowa Hakko) is named an ingredient to watch in 2026.
Winners #2: Manufacturers of "smart" pre-workouts. The pre-workout market grew 5% in 2025, with nootropic formulas being the growth driver. Optimum Nutrition Amped contains a nootropic stack with mint extract (Neumentix) and caffeine, while ESN Crank includes theobromine for "drive and focus."
Winners #3: Manufacturers of new formats — performance pouches. Ultra, a functional pouch brand, sold 1 million cans in the first six months and raised $11 million in investment. Their pouches contain paraxanthine (enfinity), L-theanine, and ginseng. Legendary boxer Mike Tyson became an ambassador for competitor brand LF*Go.
Losers: Traditional manufacturers of high-stimulant pre-workouts with excessive caffeine. The 2026 consumer no longer wants "jitters" and subsequent crashes. The market is moving toward balanced stacks where caffeine is combined with L-theanine for "calm energy." Pure caffeine without modifiers is losing share.
What the Media Isn't Saying
Insight #1: The term "nootropic" is a legally and scientifically dangerous territory.
Let's start with science. Neurologist Kristina Nazarova states directly: "There is a lack of convincing scientific evidence that the 'nootropics' on the market improve memory, attention, and other cognitive functions in healthy people." The reason is that in a healthy person, neurotransmitter balance is not disrupted — there are simply no targets for these substances to act on.
But there is also a legal problem. In the US, the term "nootropic" is not a regulated category. A substance can be sold as a dietary supplement, but still lack GRAS (Generally Recognized as Safe) status for use in conventional foods. As Dicentra explains, "a nootropic ingredient can legally be sold as a supplement, but still require a GRAS determination for use in a beverage or bar."
The most dangerous area is the gray zone of "designer nootropics." Phenibut, developed in the USSR as a military drug, is sold online in the US and Europe as a "supplement for sleep and anxiety." But the CDC recorded 1,320 cases of phenibut exposure from 2009 to 2019, 85% of which required medical attention. Phenibut causes dependence, severe withdrawal syndrome, and is dangerous when combined with other CNS depressants. The FDA explicitly states that phenibut does not meet the definition of a dietary ingredient, and products containing it are considered misbranded.
Insight #2: The race for "natural nootropics" has already begun, and Asia is leading.
The market is clearly moving toward plant-based, stimulant-free formulas. Brain Savior, launched in June 2025, offers a completely plant-based composition without stimulants. Biotropics Malaysia Berhad released BioKesum leaf extract in September 2023, with clinically confirmed flavonoids that increase BDNF (brain-derived neurotrophic factor) levels.
But the most interesting player is Japan. Kyowa Hakko, manufacturer of Cognizin (citicoline), has already incorporated its ingredient into more than 200 products worldwide. Asian manufacturers have a regulatory advantage: in Japan and Korea, "functional foods" are an established category with a 30-year history, whereas in the US and Europe, nootropics are still in a "gray zone" between supplements and drugs.
Forecast: Next 30 Days and 90 Days
Next 30 Days (June 2026):
Expect a regulatory crackdown by the FDA or EFSA on misleading labeling of nootropic products. Particularly vulnerable are companies selling "cognitive elixirs" with unproven or dangerous ingredients (like phenibut) through Amazon and TikTok Shop. There will be at least one high-profile product recall and a consumer warning.
Also, in the next 30 days, new clinical trial data on L-theanine and ashwagandha in the context of athletic performance will be released — likely confirming their effectiveness for accelerating recovery after intense exercise. This will boost sales.
90 Days (by Fall 2026):
Market consolidation will occur. Major players — PepsiCo, Unilever, Abbott — will start acquiring small innovative brands. PepsiCo is already in the race (appearing in reports as a brain health market player) but has not yet made a major acquisition. Logical targets include HVMN or Neurohacker Collective, valued at $100-200 million.
The first "personalized nootropic stacks" based on genetic testing will appear. Understanding whether you are a fast or slow caffeine metabolizer (via CYP1A2 gene polymorphisms) will allow personalized dosing and composition. This will cost from $200 for the test plus a monthly course.
Final forecast: By the end of 2026, the term "nootropic" will gradually be replaced by the broader concept of "cognitive health ingredient." Consumers will tire of the hype and want simplicity: "this helps me focus" instead of "this is my seven-ingredient nootropic stack." And manufacturers will shift from marketing "smart pills" to marketing "calm energy" and "mental endurance." Then, perhaps, the scientific community will finally catch up with the market with evidence, rather than the other way around.
— Editorial Team
